Tinygemsbreaks Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Data Highlighting Widespread Opioid Use Among Fibromyalgia Patients

(MENAFN- Investor Brand Network) Tonix Pharmaceuticals (NASDAQ: TNXP) presented data at the 2026 American Society of Clinical Psychopharmacology Annual Meeting showing that opioid use remains common among U.S. adults diagnosed with fibromyalgia despite longstanding treatment guidelines discouraging their use. Based on a retrospective analysis of more than 261,000 patients in the Symphony Health claims database, the study found that approximately 40% of commercially insured, Medicare Advantage and Medicaid patients with fibromyalgia were prescribed at least one opioid, with tramadol and oxycodone representing the most common prescriptions. Tonix said the findings underscore a gap between clinical practice and evidence-based recommendations and highlight the need for greater awareness of FDA-approved, non-opioid treatment options, including TONMYA(R), the company's recently approved fibromyalgia therapy.

To view the full press release, visit

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company's newsroom at

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

MENAFN29052026000224011066ID1111184589